MedicalResearch.com Interview with:  Jeffrey Weber, M.D, Ph.D. Senior Researcher, Moffitt Cancer Center Tampa, Florida MedicalResearch.com: What are the main findings of the study? Dr. Weber: That the PD-1 blocking antibody nivolumab has a 25% ORR with long duration of response in ipilimumab refractory patients, and that patients with prior grade 3-4 ipilimumab related immune related side effects may be safely treated with nivolumab without reproducing the prior IPI related side effects. (more…)